Aluminium acetoacetate is an aluminum containing antacid.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Aluminium acetoacetate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Aluminium acetoacetate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Aluminium acetoacetate. |
| Dabigatran etexilate | Aluminium acetoacetate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Aluminium acetoacetate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Aluminium acetoacetate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Aluminium acetoacetate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Aluminium acetoacetate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Aluminium acetoacetate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Aluminium acetoacetate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Aluminium acetoacetate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Aluminium acetoacetate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Aluminium acetoacetate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Aluminium acetoacetate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | Aluminium acetoacetate can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Aluminium acetoacetate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Aluminium acetoacetate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Aluminium acetoacetate. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium acetoacetate. |
| Captopril | Aluminium acetoacetate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium acetoacetate. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Aluminium acetoacetate. |
| Chloroquine | Aluminium acetoacetate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Aluminium acetoacetate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gabapentin enacarbil | The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Aluminium acetoacetate. |
| Hyoscyamine | Aluminium acetoacetate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Aluminium acetoacetate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Aluminium acetoacetate may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Aluminium acetoacetate may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Aluminium acetoacetate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Aluminium acetoacetate may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Quinine | Aluminium acetoacetate can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Aluminium acetoacetate. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Aluminium acetoacetate. |
| Deferasirox | Aluminium acetoacetate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Aluminium acetoacetate. |
| Fexofenadine | Aluminium acetoacetate can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Aluminium acetoacetate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Aluminium acetoacetate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mesalazine | Aluminium acetoacetate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Aluminium acetoacetate. |
| Ursodeoxycholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Aluminium acetoacetate can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Aluminium acetoacetate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Obeticholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Obeticholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Aluminium acetoacetate can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| cis-Diamminechlorocholylglycinateplatinum(II) | The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium acetoacetate. |
| Dehydrocholic acid | Aluminium acetoacetate can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Aluminium acetoacetate can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aramchol | The serum concentration of Aramchol can be decreased when it is combined with Aluminium acetoacetate. |
| Ox bile extract | The serum concentration of Ox bile extract can be decreased when it is combined with Aluminium acetoacetate. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Aluminium acetoacetate. |
| Ketoconazole | Aluminium acetoacetate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiethylperazine | Aluminium acetoacetate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promazine | Aluminium acetoacetate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prochlorperazine | Aluminium acetoacetate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorpromazine | Aluminium acetoacetate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Triflupromazine | Aluminium acetoacetate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluphenazine | Aluminium acetoacetate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioridazine | Aluminium acetoacetate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Moricizine | Aluminium acetoacetate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trifluoperazine | Aluminium acetoacetate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine | Aluminium acetoacetate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mesoridazine | Aluminium acetoacetate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetophenazine | Aluminium acetoacetate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Aluminium acetoacetate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Alimemazine | Aluminium acetoacetate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrimeprazine | Aluminium acetoacetate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Periciazine | Aluminium acetoacetate can cause a decrease in the absorption of Periciazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acepromazine | Aluminium acetoacetate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aceprometazine | Aluminium acetoacetate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipotiazine | Aluminium acetoacetate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thioproperazine | Aluminium acetoacetate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| BL-1020 | Aluminium acetoacetate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cyamemazine | Aluminium acetoacetate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylene blue | Aluminium acetoacetate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propiopromazine | Aluminium acetoacetate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perazine | Aluminium acetoacetate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Butaperazine | Aluminium acetoacetate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlorproethazine | Aluminium acetoacetate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Thiazinam | Aluminium acetoacetate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dixyrazine | Aluminium acetoacetate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perphenazine enanthate | Aluminium acetoacetate can cause a decrease in the absorption of Perphenazine enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Aluminium acetoacetate. |
| Doxycycline | Aluminium acetoacetate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lymecycline | Aluminium acetoacetate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clomocycline | Aluminium acetoacetate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxytetracycline | Aluminium acetoacetate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demeclocycline | Aluminium acetoacetate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetracycline | Aluminium acetoacetate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metacycline | Aluminium acetoacetate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Minocycline | Aluminium acetoacetate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarecycline | Aluminium acetoacetate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omadacycline | Aluminium acetoacetate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |